May 24, 2019 / 8:23 PM / 4 months ago

BRIEF-Novartis says FDA Approves Novartis Piqray

May 24 (Reuters) - Novartis AG:

* FDA APPROVES NOVARTIS PIQRAY® - THE FIRST AND ONLY TREATMENT SPECIFICALLY FOR PATIENTS WITH A PIK3CA MUTATION IN HR+/HER2- ADVANCED BREAST CANCER

* US FOOD AND DRUG ADMINISTRATION HAS APPROVED PIQRAY Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below